- Home
- PLX vs LNSR Comparison
PLX vs LNSR Comparison
Compare PLX & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | LNSR |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 136.8M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLX | LNSR |
|---|---|---|
| Price | $2.07 | $12.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 825.9K | 32.9K |
| Earning Date | 03-16-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $61,840,000.00 | $59,141,000.00 |
| Revenue This Year | $14.29 | $19.55 |
| Revenue Next Year | $16.65 | $35.89 |
| P/E Ratio | $30.69 | ★ N/A |
| Revenue Growth | ★ 35.41 | 21.02 |
| 52 Week Low | $1.32 | $8.96 |
| 52 Week High | $3.10 | $17.31 |
Technical Indicators
Market Signals| Indicator | PLX | LNSR |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 61.37 |
| Support Level | $2.03 | $12.12 |
| Resistance Level | $2.11 | $12.85 |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 81.69 | 63.87 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.